These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29130101)

  • 1. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
    Sheng W; Gong J; Jiang M; Zhen Y
    Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.
    He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y
    Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
    Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
    Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
    Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
    Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel fusion protein NGR-sIL-24 for targetedly suppressing cancer cell growth via apoptosis.
    Valiyari S; Salimi M; Bouzari S
    Cell Biol Toxicol; 2020 Apr; 36(2):179-193. PubMed ID: 32239369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
    Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
    Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.
    Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS
    Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
    Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
    Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
    Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
    Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
    Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
    Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimization of the preparation process for fusion protein Fv-LDP that composes lidamycin apoprotein and single-chain Fv antibody directed against type IV collagenase].
    Gao RJ; Zhao CY; Li DD; Zhen YS
    Yao Xue Xue Bao; 2013 Oct; 48(10):1563-9. PubMed ID: 24417083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.